Oral Testosterone vs Injections for Low Testosterone
Updated November 20, 2026
JATENZO, TLANDO and KYZATREX are the three FDA-approved oral testosterone undecanoate capsules, and the trials listed here are the evidence for how they compare with other products. No trial listed here compared an FDA-approved testosterone capsule with an injection. The FDA states that ambulatory blood pressure studies confirmed a blood pressure increase with all testosterone products, class-wide. The three capsule trials listed here compared a capsule with a topical testosterone product or with nothing, so none of them shows how a capsule compares with an injection. The labels direct prescribers to monitor blood pressure and hematocrit during treatment.
Route-by-Route Comparison of FDA Status and Labeled Risks
Every delivery route for testosterone therapy carries distinct regulatory approvals, labeled risks, and monitoring requirements.
| Route and example product | FDA status and labeled use | Schedule III designation | Blood pressure language | Other label content |
|---|---|---|---|---|
| Oral undecanoate capsules (JATENZO, TLANDO, KYZATREX) | FDA-approved for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (primary and hypogonadotropic hypogonadism). Limitation of use: safety and efficacy in age-related hypogonadism or males under 18 not established. | Schedule III controlled substance (CIII) | Section 5.4 warns of blood pressure increases; periodic monitoring required; not recommended in uncontrolled hypertension. | Absorbed through intestinal lymphatics into blood circulation, circumventing liver first-pass metabolism; section 5.8 warns of hepatic risks associated with 17-alpha-alkyl androgens; warns of hematocrit increases and possible azoospermia. |
| Oral methyltestosterone tablets (METHITEST) | FDA-approved for replacement therapy in hypogonadal males. Limitation of use: safety and efficacy in age-related hypogonadism not established. | CIII | Label carries blood pressure language. | Label warns prolonged high-dose use is associated with peliosis hepatis, hepatic neoplasms, hepatocellular carcinoma, cholestatic hepatitis, and jaundice at relatively low doses. |
| Intramuscular testosterone cypionate injection (DEPO-Testosterone) | FDA-approved for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. Limitation of use: safety and efficacy in age-related hypogonadism not established. | CIII | Warns testosterone can increase blood pressure, which can increase cardiovascular risk over time; periodic monitoring required; not recommended in uncontrolled hypertension. | Oil solution for intramuscular administration; label instructs that hemoglobin and hematocrit should be checked periodically in patients receiving long-term androgen administration. |
| Subcutaneous enanthate injection (XYOSTED) | FDA-approved for replacement therapy in adult males for primary and hypogonadotropic hypogonadism. Limitation of use: safety and efficacy in age-related hypogonadism or males under 18 not established. | CIII | Section 5.4 warns of blood pressure increases; clinical trial ambulatory monitoring showed mean systolic/diastolic rise of 3.9/1.5 mm Hg after 12 weeks. | Subcutaneous injection formulation; label warns of polycythemia and blood pressure elevation requiring regular monitoring. |
| Intramuscular undecanoate injection (AVEED) | FDA-approved for replacement therapy in adult males for primary and hypogonadotropic hypogonadism. Limitation of use: safety and efficacy in age-related hypogonadism or males under 18 not established. | CIII | Label carries blood pressure language. | Boxed Warning for serious pulmonary oil microembolism (POME) reactions and anaphylaxis; available only through the restricted AVEED Risk Evaluation and Mitigation Strategy (REMS) Program with post-injection healthcare setting observation. |
| Compounded troches (lozenges) | Not FDA-approved. FDA compounding guidance states that the agency does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed. | Not addressed in the sources reviewed | Not addressed in the sources reviewed | Compounded preparations are not FDA-approved; FDA does not verify safety, effectiveness, or quality before marketing. |
The blood pressure averages quoted in FDA labels come from separate clinical trials conducted in different patient groups over different durations. They do not represent a head-to-head comparison or clinical ranking.
FDA-Labeled Capsules Containing Testosterone Undecanoate
Three oral testosterone undecanoate capsules hold FDA approval for prescription use in the United States: JATENZO, TLANDO, and KYZATREX. Each product is classified under federal law as a Schedule III (CIII) controlled substance. Their FDA-approved indication covers testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
This labeled indication specifies two diagnostic categories:
- Primary hypogonadism (congenital or acquired), which includes testicular failure resulting from conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals.
- Hypogonadotropic hypogonadism (congenital or acquired), which includes idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, as well as pituitary-hypothalamic injury caused by tumors, trauma, or radiation.
Each product label carries an explicit Limitation of Use stating that safety and efficacy in men with age-related hypogonadism have not been established. The JATENZO, KYZATREX, XYOSTED, and AVEED labels also state that safety and efficacy in males under 18 years of age have not been established. An FDA safety communication confirms that this Limitation of Use remains retained class-wide across testosterone treatments.
The pharmacokinetic design of testosterone undecanoate separates it from historical oral androgens. According to the TLANDO prescribing information, testosterone undecanoate is a lipophilic molecule absorbed primarily into the intestinal lymphatic system after oral ingestion. It enters the general blood circulation directly through the thoracic duct. This mechanism avoids initial absorption into the portal vein, circumventing first-pass metabolism in your liver.
Blood Pressure After the 2025 Labeling Change
On February 28, 2025, the FDA issued a Drug Safety Communication announcing class-wide labeling changes for testosterone products. The FDA completed a review of data from the TRAVERSE cardiovascular safety trial (which evaluated a transdermal topical gel formulation) alongside postmarket ambulatory blood pressure monitoring (ABPM) studies. Based on this evidence, the FDA stated that completed ABPM studies confirmed an increase in blood pressure with the use of all testosterone products, class-wide.
Following this review, the FDA removed the prior Boxed Warning titled "Blood Pressure Increases" from the labels of JATENZO, TLANDO, KYZATREX, and the injectable enanthate XYOSTED. The blood pressure warning was relocated to section 5.4 under Warnings and Precautions. Older medical articles describing oral testosterone undecanoate as a boxed-warning medication are now outdated.
The specific blood pressure values documented in FDA prescribing information reflect separate clinical study protocols:
- The JATENZO label states that 24-hour ambulatory blood pressure monitoring demonstrated an average systolic and diastolic blood pressure increase of 4.9 and 2.5 mm Hg from baseline after 4 months of treatment. In patients receiving concurrent antihypertensive therapy, the mean increase was 5.4 systolic and 3.2 diastolic mm Hg. The label notes that average blood pressures had not plateaued at the conclusion of the trial.
- The TLANDO label states that in Study 18-001, ambulatory monitoring showed a mean systolic and diastolic blood pressure rise of 4.3 and 1.4 mm Hg from baseline after 4 months. For men on antihypertensive medications, the mean increase was 4.8 systolic and 1.6 diastolic mm Hg. The label warns that blood pressure increases can raise cardiovascular risk over time.
- The KYZATREX label reports that ambulatory monitoring showed an average systolic and diastolic blood pressure increase of 1.7 and 0.6 mm Hg from baseline after 4 months of treatment. In men on background antihypertensive therapy, the mean increase was 3.4 systolic and 0.7 diastolic mm Hg.
- The XYOSTED subcutaneous injection label notes that ambulatory monitoring showed an average systolic and diastolic blood pressure increase of 3.9 and 1.5 mm Hg from baseline after 12 weeks of treatment.
- The DEPO-Testosterone intramuscular cypionate label states that testosterone can increase blood pressure, which can increase cardiovascular risk over time, and directs prescribers to monitor blood pressure periodically.
Peer-reviewed studies of the three capsules, each with authors employed by the product developer, report these ambulatory blood pressure results. In a 2021 study in the Journal of Clinical Hypertension, White WB et al. evaluated 155 hypogonadal men taking Kyzatrex and recorded a mean systolic ambulatory blood pressure increase of 1.7 mm Hg (95% confidence interval [CI] 0.3 to 3.1) at day 120. In a 2021 study in the Journal of Cardiovascular Pharmacology and Therapeutics, White WB et al. evaluated 138 men taking Tlando and recorded a mean 24-hour systolic increase of 3.8 mm Hg along with a 3.2% rise in hematocrit. Men in the highest quartile of hematocrit change (increases of 6% to 14%) experienced a mean systolic increase of 8.3 mm Hg, leading the authors to conclude that hematocrit changes may help identify patients developing greater blood pressure increases. In a 2020 study in the Journal of Clinical Endocrinology and Metabolism, Swerdloff RS et al. reported that oral testosterone undecanoate in the Jatenzo phase 3 trial was associated with a mean systolic ambulatory blood pressure increase of 3 to 5 mm Hg.
These study averages come from separate patient cohorts observed under distinct research protocols. They do not constitute a direct comparison or clinical hierarchy among products. The clinical takeaway across all seven FDA labels evaluated is consistent: oral capsules and injectable solutions both carry warnings regarding blood pressure elevation. Selecting an oral capsule does not eliminate the need for cardiovascular surveillance. The labels direct prescribers to monitor blood pressure periodically, especially in men with hypertension.
Liver Language on Older Oral Tablets and Undecanoate Capsules
Concerns regarding oral testosterone and liver damage stem from older 17-alpha-alkylated oral androgens. The prescribing information for METHITEST (methyltestosterone tablets) warns that prolonged use of high doses of 17-alpha-alkylandrogens is associated with serious hepatic adverse effects. These include peliosis hepatis (which can be a life-threatening or fatal complication), hepatic neoplasms including hepatocellular carcinoma, and cholestatic hepatitis with jaundice at relatively low doses.
Modern oral testosterone undecanoate capsules do not share this 17-alpha-alkylated chemical structure. Section 5.8 of the KYZATREX prescribing information states explicitly that KYZATREX is not a 17-alpha-alkyl androgen and is not known to cause hepatic adverse effects. The TLANDO and JATENZO prescribing information explain that the severe hepatic effects documented with oral androgens apply to 17-alpha-alkylated compounds like methyltestosterone.
Because testosterone undecanoate is absorbed through your intestinal lymphatic system, it enters systemic circulation via the thoracic duct. This route bypasses the portal vein and avoids first-pass hepatic metabolism. Nevertheless, FDA labels for all three oral undecanoate products retain a section 5.8 titled "Hepatic Adverse Effects" that outlines the historical risks observed with alkylated androgens. The regulatory record does not justify claiming that oral undecanoate carries zero liver risk under any clinical circumstance.
Hematocrit Checks on Oral and Injectable Testosterone
Elevated hematocrit (polycythemia) is a labeled warning on the oral and injectable labels we read.
Prescribing information across formulations instructs prescribers to monitor this marker:
- The DEPO-Testosterone label directs prescribers to check hemoglobin and hematocrit periodically in patients receiving long-term androgen administration.
- The JATENZO, TLANDO, and KYZATREX labels instruct prescribers to evaluate baseline hematocrit prior to initiating treatment and to continue monitoring hematocrit periodically while treatment continues.
In a 2022 systematic review and Bayesian network meta-analysis published in the Journal of Urology, Nackeeran S et al. evaluated 29 randomized, placebo-controlled trials encompassing 3,393 men. The authors noted that direct head-to-head clinical trials comparing testosterone formulations are rare, requiring indirect network comparisons to assess hematocrit changes across delivery methods.
The analysis revealed that mean hematocrit increased significantly compared to placebo across every examined testosterone route:
- Oral testosterone undecanoate: 4.3% increase (95% confidence interval [CI] 0.7 to 8.0)
- Intramuscular testosterone enanthate or cypionate: 4.0% increase (95% CI 2.9 to 5.1)
- Transdermal testosterone gel: 3.0% increase (95% CI 1.8 to 4.3)
- Intramuscular testosterone undecanoate: 1.6% increase (95% CI 0.3 to 3.0)
- Transdermal testosterone patch: 1.4% increase (95% CI 0.2 to 2.6)
The authors detected no difference in hematocrit change between oral undecanoate and the intramuscular formulations in this indirect comparison, and wrote that the clinical concern of the increase remains questionable. The oral estimate has a wide interval (0.7 to 8.0), so the analysis cannot show the routes raise hematocrit equally. The DEPO-Testosterone, JATENZO, TLANDO and KYZATREX labels each direct prescribers to check hematocrit during treatment.
What the Trials Compared
Phase 3 trials of oral testosterone undecanoate evaluated whether capsules could restore serum testosterone to normal physiological ranges. However, none of the three trials listed here compared oral undecanoate directly against an injectable testosterone formulation.
In the Jatenzo phase 3 trial published by Swerdloff RS et al. in the Journal of Clinical Endocrinology and Metabolism (2020), researchers conducted a randomized, active-controlled, open-label trial comparing oral testosterone undecanoate in 166 men against a topical testosterone product (Axiron) in 56 men over 3 to 4 months. The trial found that 87% of men in both the oral and topical groups achieved average testosterone concentrations within the normal eugonadal range. Safety profiles were similar between groups, apart from the ambulatory systolic blood pressure elevation observed in the oral cohort.
None of the three trials used an injection as the comparator. In the Tlando phase 3 trial published in Andrology (2025), investigators randomized 315 hypogonadal men in a 2:1 ratio to receive either oral testosterone undecanoate or a 1.62% transdermal topical testosterone gel. Following protocol titration, 87.4% of patients receiving oral testosterone undecanoate achieved a 24-hour average total testosterone concentration within the normal reference range (300 to 1140 ng/dL).
In the Kyzatrex phase 3 trial published in Therapeutic Advances in Urology (2024), investigators conducted an open-label, single-arm, 6-month trial in 155 hypogonadal men without a control or comparator group. In that trial, 87.8% of participants in a worst-case analysis and 96.1% of men who completed 90 days of therapy achieved normal mean plasma testosterone concentrations. The trial recorded a mean ambulatory systolic blood pressure increase of 1.7 mm Hg and reported no drug-related serious adverse events.
As Nackeeran S et al. (2022) highlighted in their systematic review, head-to-head clinical trials comparing distinct testosterone routes directly remain rare. The three trials reported 87%, 87.4% and 87.8% in range, each with a different comparator or none, and different endpoint definitions. Because the trials listed here evaluated oral capsules against a topical testosterone product or used no active comparator, the evidence does not show that capsules perform identically, superiorly, or inferiorly to injectable esters.
Broader cardiovascular safety evidence also relies on transdermal rather than oral or injectable data. The TRAVERSE trial (Lincoff AM et al., published in the New England Journal of Medicine in 2023) evaluated cardiovascular outcomes in 5,246 men aged 45 to 80 with hypogonadism and preexisting or high risk of cardiovascular disease. TRAVERSE found testosterone gel noninferior to placebo for major adverse cardiac events (7.0% vs 7.3%; hazard ratio 0.96, 95% CI 0.78 to 1.17), and the testosterone group had a higher incidence of atrial fibrillation, acute kidney injury and pulmonary embolism. However, the testosterone arm in TRAVERSE utilized a daily transdermal 1.62% topical gel formulation, not an oral capsule or an injection.
Compounded Troches and Their FDA Status
Testosterone troches are dissolvable lozenges. Troches are lozenges that are compounded rather than commercially manufactured drugs.
The FDA addresses compounded drug safety in its official regulatory guidance, "Compounding and the FDA: Questions and Answers": "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed."
Compounded testosterone troches are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before they are marketed. If you are evaluating compounded options, your physician can explain how unapproved compounded lozenges differ from FDA-approved prescription therapies.
Factors in a Prescriber's Route Decision
Selecting between oral capsules, intramuscular injections, and subcutaneous injections involves evaluating several diagnostic, cardiovascular, and practical factors. A qualified clinician reviews these variables before prescribing any treatment protocol:
- Cardiovascular and blood pressure status: Because FDA-reviewed ambulatory monitoring confirms that all testosterone products can raise blood pressure class-wide, your resting blood pressure is a baseline measurement. The JATENZO, TLANDO, KYZATREX and DEPO-Testosterone labels state the product is not recommended for use in men with uncontrolled hypertension.
- Formulation-specific safety profiles: Injectable therapies have distinct administration considerations. DEPO-Testosterone is an intramuscular cypionate oil solution, while XYOSTED provides a subcutaneous enanthate injection. In contrast, the intramuscular undecanoate injection AVEED carries a Boxed Warning for serious pulmonary oil microembolism (POME) reactions and anaphylaxis. Symptoms of POME include coughing urges, dyspnea, throat tightening, chest pain, dizziness, and syncope. Because of these reactions, AVEED is available only through a restricted distribution program called the AVEED REMS Program, requiring post-injection observation in a healthcare setting. Oral undecanoate capsules carry no POME warning and no REMS program mandate.
- Clinical eligibility guidelines: The Endocrine Society 2018 clinical practice guideline (Bhasin S et al.) recommends diagnosing hypogonadism only in men with consistent symptoms and signs of deficiency confirmed by fasting morning total testosterone measurements on two separate occasions. The guideline recommends against starting testosterone therapy in men planning near-term fertility, men with elevated baseline hematocrit, active prostate cancer, palpable prostate nodules, severe untreated obstructive sleep apnea, uncontrolled heart failure, or a myocardial infarction or stroke within the past 6 months.
- Spermatogenesis and fertility: Section 5.7 of the KYZATREX prescribing information states that exogenous testosterone therapy may suppress spermatogenesis and cause azoospermia. The JATENZO, KYZATREX, DEPO-Testosterone and AVEED labels each describe possible suppression of spermatogenesis, so an oral route does not remove this concern. Selecting an oral delivery route does not protect your reproductive function if you are planning to father children.
- Related comparisons: You can explore how non-oral therapies operate by reviewing our comparisons of pellets compared with injections and injections compared with cream.
Your physician reviews your diagnostic blood tests, cardiovascular risk profile, and lifestyle preferences to determine whether oral capsules or injectable options represent the most clinically sound approach for your care.
Who This Comparison Is Not For
This comparison is not intended for men whose low testosterone levels stem solely from normal aging. The FDA labels for JATENZO, KYZATREX, DEPO-Testosterone, XYOSTED, AVEED, and METHITEST each state that the safety and efficacy of testosterone therapy have not been established in men with age-related hypogonadism. If you do not have an underlying, documented medical condition causing your testosterone deficiency, initiating replacement therapy falls outside labeled indications.
This comparison is also not for men who are actively planning to conceive children in the near term. The Endocrine Society clinical guidelines advise against starting testosterone therapy in men pursuing fertility, and product labels state that exogenous testosterone may suppress spermatogenesis and may lead to azoospermia. If you want children, sperm production is a conversation to have with your physician before you start any testosterone treatment.
Pricing is covered in our testosterone replacement therapy (TRT) cost guide. Dosing schedules are set by your prescribing doctor based on your personal lab numbers. If you meet the clinical criteria for treatment, consult a licensed physician to evaluate your diagnostic markers and discuss appropriate prescription therapies.
What Would Change the Answer
The clinical considerations surrounding oral testosterone vs injections could shift if new medical evidence or regulatory actions emerge:
- A direct, randomized head-to-head clinical trial comparing oral testosterone undecanoate capsules against injectable testosterone esters, evaluating total testosterone bioavailability, symptom resolution, blood pressure, and hematocrit over a multi-year period.
- An updated FDA safety communication or revised prescribing information that alters the monitoring intervals, indication boundaries, or cardiovascular guidance for specific testosterone formulations.
- The regulatory approval of a novel oral androgen formulation featuring distinct metabolic pathways or improved pharmacokinetic consistency.
- A change in your individual clinical profile, such as an unmanaged rise in resting blood pressure, elevated hematocrit on quarterly labs, a new cardiovascular diagnosis, or an update to your family planning goals.
Blood pressure readings, hematocrit results and your medical history are what a physician weighs when revisiting the route.
The Opt Take on Oral Testosterone vs Injections
The label and trial record above does not rank the routes, so the route decision rests on your blood pressure, hematocrit, fertility plans and diagnosis. At Opt Health, we view delivery route as one clinical decision within a broader medical protocol.
Our physician-led telehealth membership focuses on preventive longevity and comprehensive health optimization. Every protocol begins with an in-depth blood panel evaluating 55+ biomarkers, completed either at home or at a partner laboratory. An Opt Health physician sits down with you for a 1:1 video consultation to review your hormone levels, cardiovascular markers, and other biomarkers. If treatment is clinically indicated, your physician selects a personalized plan tailored to your profile. Prescriptions are shipped directly from our pharmacy to your door. Because hormone optimization requires active oversight, our care model includes reassessment lab panels and physician consultations every 3 to 4 months to measure how your body responds and adjust your plan over time.
Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.
Frequently Asked Questions
Modern oral testosterone undecanoate capsules (JATENZO, TLANDO, KYZATREX) are FDA-approved. The KYZATREX label states the product is not a 17-alpha-alkyl androgen and is not known to cause hepatic adverse effects, and the TLANDO label says it is not known to produce the hepatic effects associated with 17-alpha-alkyl androgens. All three capsule labels still carry warnings on blood pressure, hematocrit and hepatic effects. An FDA safety communication issued in February 2025 confirmed that all testosterone products, including oral capsules and injections, increase blood pressure in ambulatory monitoring studies. Prescribing information also warns of increased hematocrit and potential cardiovascular risks.
Older oral androgens such as methyltestosterone are 17-alpha-alkylated compounds associated with severe liver complications, including peliosis hepatis, liver tumors, and cholestatic jaundice. Newer FDA-approved oral testosterone undecanoate capsules are absorbed through your intestinal lymphatic system, bypassing the liver's portal vein and avoiding first-pass metabolism. The KYZATREX label states it is not a 17-alpha-alkyl androgen and is not known to cause hepatic adverse effects, although all oral undecanoate labels still retain a section on hepatic risks.
Clinical trials have not established that oral testosterone undecanoate capsules work as well as injections because direct head-to-head trials between them are rare. The three capsule trials reported 87%, 87.4% and 87.8% in range, each with a different comparator or none, and different endpoint definitions. A 2022 network meta-analysis in the Journal of Urology found no detectable difference in hematocrit change between oral undecanoate and injectable formulations in an indirect comparison. None of the three capsule trials above compared a capsule with an injection.
Yes. In clinical trials using ambulatory blood pressure monitoring, oral testosterone undecanoate capsules increased average systolic blood pressure by 1.7 to 4.9 mm Hg after 4 months of use, with higher mean increases seen in men taking antihypertensive medications. The FDA's February 2025 safety communication confirmed that blood pressure increases occur across all testosterone products class-wide. The JATENZO, TLANDO, KYZATREX and DEPO-Testosterone labels instruct prescribers to monitor blood pressure periodically and state that testosterone products are not recommended for use in men with uncontrolled hypertension.
No, compounded testosterone troches are not FDA-approved. As the FDA outlines in its formal compounding guidance, the agency does not evaluate compounded medications for clinical safety, effectiveness, or quality before they are marketed to patients. Troches are lozenges that are compounded rather than commercially manufactured drugs.
You can review the components of treatment pricing in our testosterone replacement therapy (TRT) cost breakdown. Your prescribing doctor can help you assess the overall cost of medication and routine laboratory oversight before you begin a protocol.
Comparing oral testosterone with injections starts with your own numbers. An Opt Health membership includes a 55+ biomarker panel and a 1:1 physician consultation, then repeats testing every 3 to 4 months.
References
- FDA Drug Safety Communication. FDA issues class-wide labeling changes for testosterone products. February 28, 2025. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-issues-class-wide-labeling-changes-testosterone-products
- JATENZO (testosterone undecanoate) capsules prescribing information. DailyMed set id ed7b5d41-7475-4c10-99b9-b62b3434ae60. Published October 15, 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ed7b5d41-7475-4c10-99b9-b62b3434ae60
- TLANDO (testosterone undecanoate) capsules prescribing information. DailyMed set id 4b0b92e9-6d3c-a0e5-e1c7-342999f72580. Published March 12, 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4b0b92e9-6d3c-a0e5-e1c7-342999f72580
- KYZATREX (testosterone undecanoate) capsules prescribing information. DailyMed set id 7f7167a7-2a25-47e2-acf5-33f499fce971. Published October 08, 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7f7167a7-2a25-47e2-acf5-33f499fce971
- DEPO-Testosterone (testosterone cypionate) injection prescribing information. DailyMed set id cfbb53d4-b868-4a28-8436-f9112eb01c39. Published November 13, 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=cfbb53d4-b868-4a28-8436-f9112eb01c39
- XYOSTED (testosterone enanthate) subcutaneous injection prescribing information. DailyMed set id 8a3d204c-be26-49e0-8599-0ac12a272e81. Published April 27, 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8a3d204c-be26-49e0-8599-0ac12a272e81
- AVEED (testosterone undecanoate) injection prescribing information. DailyMed set id f80f025b-17d8-40af-8739-20ce07902045. Published March 18, 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f80f025b-17d8-40af-8739-20ce07902045
- METHITEST (methyltestosterone) tablets prescribing information. DailyMed set id 77bb4ef4-c10e-4acc-8225-651d003f4561. Published June 05, 2025. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=77bb4ef4-c10e-4acc-8225-651d003f4561
- Food and Drug Administration. Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018;103(5):1715-1744. PMID 29562364. https://pubmed.ncbi.nlm.nih.gov/29562364/
- Lincoff AM, et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). N Engl J Med 2023;389(2):107-117. PMID 37326322. https://pubmed.ncbi.nlm.nih.gov/37326322/
- Swerdloff RS, et al. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. J Clin Endocrinol Metab 2020;105(8):2515-2531. PMID 32382745. https://pubmed.ncbi.nlm.nih.gov/32382745/
- White WB, et al. Effects of the oral testosterone undecanoate Kyzatrex on ambulatory blood pressure in hypogonadal men. J Clin Hypertens 2021;23(7):1420-1430. PMID 34114726. https://pubmed.ncbi.nlm.nih.gov/34114726/
- White WB, et al. Effects of a Novel Oral Testosterone Undecanoate on Ambulatory Blood Pressure in Hypogonadal Men (TLANDO). J Cardiovasc Pharmacol Ther 2021;26(6):630-637. PMID 34191621. https://pubmed.ncbi.nlm.nih.gov/34191621/
- Nackeeran S, et al. The Effect of Route of Testosterone on Changes in Hematocrit: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Trials. J Urol 2022;207(1):44-51. PMID 34445892. https://pubmed.ncbi.nlm.nih.gov/34445892/
- Safety, efficacy, and pharmacokinetics of oral testosterone undecanoate in males with hypogonadism. Andrology 2025;13(4):882-893. PMID 39252657. https://pubmed.ncbi.nlm.nih.gov/39252657/
- A phase III, single-arm, 6-month trial of a wide-dose range oral testosterone undecanoate product. Ther Adv Urol 2024;16. PMID 38606384. https://pubmed.ncbi.nlm.nih.gov/38606384/
This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.
This article is part of our guide to testosterone replacement therapy. Read our guide to testosterone replacement therapy.
Start Today
Your health, your terms. Discover how personalized care can transform not just the way you feel, but how you live.
This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.